Project: AMR Rapid Diagnostic Tests

Acronym AMR-RDT (Reference Number: JPIAMR_2016_N008)
Duration 01/01/2017 - 31/12/2017
Project Topic Antimicrobial Resistance (AMR) has become a global threat and rapid diagnostics are urgently needed to tackle this challenge. To identify barriers to the development, implementation and use of rapid diagnostics and propose a roadmap to future solutions we are launching AMR Rapid Diagnostic Tests (AMR-RDT) as a multi-sectoral, multi-stakeholder and interdisciplinary working group with global reach. It brings together over 50 key individuals and organisations from 15 countries worldwide that are active in the field of diagnostics and antimicrobial resistance. This unprecedented body of expertise and the access it brings to national and international institutions, and networks will amplify the reach and implementation of the working group’s outputs. AMR-RDT will concentrate on five overarching topics: Need & Target Product Profiles, Technologies, Development Roadmaps, Business Models, and Behavioural Change. The working group will focus on human healthcare but also recognises the importance of One Health aspects. AMR-RDT is funded as a one-year project by the UK Medical Research Council under the frame of the Joint Planning Initiative on AMR (JPIAMR) and is coordinated by Till Bachmann at the University of Edinburgh.
Website visit project website
Network JPI AMR
Call 4th Joint Call: Research Networking Programmes

Project partner

Number Name Role Country
1 University of Edinburgh Coordinator United Kingdom
2 North Bristol NHS Trust Observer United Kingdom
3 BioMérieux Observer France
4 KTH Royal Institute of Technology Observer Sweden
5 Omega Diagnostics Observer United Kingdom
6 NIHR Diagnostic Evidence Cooperative Observer United Kingdom
7 HemoCue Observer Sweden
8 British In Vitro Diagnostics Association Observer United Kingdom
9 Foundation for Innovative New Diagnostics Observer Switzerland
10 National Institute of Clinical and Health Excellence Observer United Kingdom
11 Osaka University Observer Japan
12 World Health Organization (WHO) Observer Switzerland
13 European Diagnostics Cluster Alliance Observer France
14 R-Biopharm Observer Germany
15 Fraunhofer Institute for Cell Therapy and Immunology Observer Germany
16 Curetis GmbH Observer Germany
17 Robert Koch Institute Observer Germany
18 University of Tromsø Observer Norway
19 Lahey Hospital & Medical Center and Harvard Medical School Observer United States
20 Antwerp University Observer Belgium
21 Ben-Gurion University Observer Israel
22 Chipcare Observer Canada
23 Ahimsa Fund Observer France
24 Erasmus MC University Medical Center Observer Netherlands
25 F2G Observer United States
26 University of Barcelona Observer Spain
27 University Hospital Münster Observer Germany
28 NHS Lothian Observer United Kingdom
29 Hyrax Biosciences Observer South Africa
30 Hahn-Schickard, University of Freiburg Observer Germany
31 Global Antibiotic R&D Partnership Observer Switzerland
32 University of Edinburgh Observer United Kingdom
33 Spectromics Observer United Kingdom
34 Public Health England Observer United Kingdom
35 Maastricht University Observer Netherlands
36 Charité University Medicine Observer Germany
37 University of Manitoba Observer Canada
38 Center for Disease Dynamics, Economics & Policy Observer India
39 London School of Hygiene & Tropical Medicine Observer United Kingdom
40 University of Edinburgh Observer United Kingdom
41 Max von Pettenkofer Institute Munich Observer Germany
42 University of Geneva Observer Switzerland
43 NHS England Observer United Kingdom
44 University of Adelaide Observer Australia
45 Centre for Cellular and Molecular Platforms Observer India
46 University of Frankfurt Observer Germany
47 Farr Institute Health Informatics Research Observer United Kingdom
48 University of Bologna Observer Italy
49 KTH Royal Institute of Technology Observer Sweden
50 HHL Leipzig Graduate School of Management Observer Germany